Bexorg, Inc., a privately held techbio company, has secured $42,500,000 in a funding round to advance its platform for central nervous system (CNS) drug discovery and development. This investment underscores confidence in Bexorg's unique approach to addressing the complex challenges of neurological disorders.
The company operates the first-ever full tech stack platform designed to support CNS drug discovery and development in the human brain. At its core is a proprietary whole-brain perfusion technology, which enables the study of brain connectivity, circuit function, and disease processes. This technology aims to identify novel targets, biomarkers, and assess the effectiveness of therapeutics for neurological disorders before clinical trials. Complementing this, Bexorg's BrainEx platform generates high-fidelity human brain molecular datasets, which feed into its XO Digital application, an AI- and machine learning-centered engine for accelerating drug discovery and development. Bexorg also collaborates with the NIH and maintains an independent bioethics board.
This significant capital infusion will enable Bexorg to accelerate the development of its proprietary platforms and expand its research capabilities. The funds are earmarked to further support its strategic partnerships with leading neuroscience companies, integrating its platform into CNS clinical development programs, and advancing its in-house neurodegeneration assets. The investment is crucial for scaling operations and enhancing the company's scientific infrastructure.
Bexorg is positioned to continue transforming the landscape of CNS drug discovery. With this funding, the company plans to deepen its scientific investigations and expand its collaborative efforts, ultimately aiming to develop more effective treatments for neurological conditions and bring meaningful solutions to patients.
